SCHEMBL366867

SCHEMBL366867

N#Cc1ccc(Oc2ccc(Cl)cc2)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.50
AR P10275 3/20 0.48
TBXA2R P21731 3/20 0.47
KCNH2 Q12809 4/20 0.44
SLC6A4 P31645 4/20 0.44
HTR2A P28223 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EPAS1 Q99814 3/20 0.43
MERTK Q12866 1/20 0.43
CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13343061 0.90 FFAR1 (0.47) FFAR1ARTBXA2RKCNH2SLC6A4
SCHEMBL11117166 0.84 FFAR1 (0.53) FFAR1ARTBXA2RMEN1KMT2A
SCHEMBL365412 0.83 FFAR1 (0.52) FFAR1ARSLC6A4EPAS1CYP19A1
SCHEMBL29255047 0.81 AR (0.48) ARTBXA2RKCNH2SLC6A4HTR2A
SCHEMBL20554635 0.81 TBXA2R (0.50) FFAR1ARTBXA2RKCNH2SLC6A4
SCHEMBL16319500 0.81 AR (0.48) FFAR1ARTBXA2RKCNH2SLC6A4
SCHEMBL20554608 0.79 AR (0.75) ARTBXA2RKCNH2SLC6A4HTR2A
SCHEMBL365516 0.79 SLC6A4 (0.64) ARKCNH2SLC6A4SLC6A3
SCHEMBL15067954 0.77 FFAR1 (0.47) FFAR1ARTBXA2RSLC6A4KDM4E
SCHEMBL11649803 0.77 SLC6A4 (0.57) FFAR1ARTBXA2RKCNH2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593433-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-26 EP disclosed
EP-2593433-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-26 EP disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
EP-2593433-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
WO-2012007877-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007877-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116285-A1 Chemical Compounds SCN1A, SCN10A, SCN1B FFAR1 1258/4885AR 3228/4885TBXA2R 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.